Global Trust Asset Management LLC Makes New $2.32 Million Investment in Astera Labs, Inc. $ALAB

Global Trust Asset Management LLC bought a new position in Astera Labs, Inc. (NASDAQ:ALAB) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 11,852 shares of the company’s stock, valued at approximately $2,321,000. Astera Labs makes up about 1.0% of Global Trust Asset Management LLC’s portfolio, making the stock its 21st largest holding.

Other hedge funds have also made changes to their positions in the company. Royal Bank of Canada raised its stake in Astera Labs by 167.3% during the 1st quarter. Royal Bank of Canada now owns 152,453 shares of the company’s stock valued at $9,097,000 after purchasing an additional 95,409 shares during the period. AQR Capital Management LLC grew its holdings in shares of Astera Labs by 213.4% during the first quarter. AQR Capital Management LLC now owns 11,391 shares of the company’s stock valued at $680,000 after buying an additional 7,756 shares in the last quarter. Empowered Funds LLC raised its position in Astera Labs by 917.3% during the first quarter. Empowered Funds LLC now owns 4,639 shares of the company’s stock valued at $277,000 after buying an additional 4,183 shares during the period. Jackson Square Capital LLC purchased a new stake in Astera Labs in the 2nd quarter worth about $294,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in Astera Labs during the 2nd quarter valued at about $431,000. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Insider Buying and Selling

In related news, COO Sanjay Gajendra sold 90,459 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $144.69, for a total value of $13,088,512.71. Following the completion of the sale, the chief operating officer directly owned 1,599,750 shares in the company, valued at approximately $231,467,827.50. The trade was a 5.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Manuel Alba sold 150,000 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $166.18, for a total value of $24,927,000.00. Following the transaction, the director owned 1,574,498 shares in the company, valued at approximately $261,650,077.64. This trade represents a 8.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 576,936 shares of company stock valued at $87,409,540. 12.50% of the stock is owned by corporate insiders.

Astera Labs Stock Up 1.3%

ALAB stock opened at $174.45 on Friday. The firm has a 50 day moving average of $159.47 and a two-hundred day moving average of $165.12. Astera Labs, Inc. has a 12 month low of $47.13 and a 12 month high of $262.90. The company has a market capitalization of $29.46 billion, a price-to-earnings ratio of 157.16, a P/E/G ratio of 2.35 and a beta of 1.50.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.10. The business had revenue of $230.58 million during the quarter, compared to analyst estimates of $206.42 million. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. Astera Labs’s quarterly revenue was up 103.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. On average, research analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Astera Labs in a research report on Wednesday. They issued an “outperform” rating and a $225.00 price target for the company. BNP Paribas Exane assumed coverage on shares of Astera Labs in a research note on Thursday, November 20th. They issued an “outperform” rating and a $225.00 price objective on the stock. Northland Securities lifted their target price on shares of Astera Labs from $175.00 to $195.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Citigroup restated an “outperform” rating on shares of Astera Labs in a report on Tuesday, December 9th. Finally, Zacks Research lowered Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $190.63.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.